REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Frequently asked questions
What sector does REGENXBIO Inc (RGNX) operate in?
REGENXBIO Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is REGENXBIO Inc (RGNX) current stock price?
As of the latest data, REGENXBIO Inc stock price is $6.58, with a previous close of $6.68. REGENXBIO Inc lost -$0.10 in the last trading session, representing a -1.5% loss.
What is REGENXBIO Inc (RGNX) current market capitalization?
REGENXBIO Inc market cap is approximately 434.37 million.
What is REGENXBIO Inc (RGNX) Earnings Per Share (EPS)?
The trailing EPS is -$3.78, and the forward EPS is -$2.98.
What is REGENXBIO Inc (RGNX) EBITDA?
REGENXBIO Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 34.26 million.
Does REGENXBIO Inc (RGNX) pay dividends?
No. REGENXBIO Inc does not pay a dividend.
How did REGENXBIO Inc (RGNX) perform in its most recent earnings report?
In the last report (June 30, 2026), REGENXBIO Inc posted an EPS surprise of 258.33% and a revenue surprise of 11.99%.
When is REGENXBIO Inc (RGNX) next earnings report?
REGENXBIO Inc is expected to release its next earnings report on September 30, 2026.
What is REGENXBIO Inc (RGNX) beta (volatility) score?
REGENXBIO Inc has a beta of 1.129, meaning its volatility is roughly in line with the market.
